## Prior Authorization Request Form for ixazomib (Ninlaro)



#### JOHNS HOPKINS HEALTHCARE

7231 Parkway Drive, Suite 100, Hanover, MD 21076

#### FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

### **USFHP Pharmacy Prior Authorization Form**

To be completed by Requesting provider			
Drug Name:	Strength:		
Dosage/Frequency (SIG):	Duration of Therapy:		

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information (please print):					
1	Patient N	Name:	Physician Name:			
	Address: Address:		Address:			
	Sponsor		Phone #:			
Date of Birth: Secure Fax #:			Secure Fax #:			
Step	Please complete the clinical assessment:					
2		Is the patient GREATER THAN or EQUAL to 18 years of age?	B □ Yes	□ No		
	years		Proceed to question 2	STOP		
				Coverage not approved		
		Is the requested medication being prescribed by or consultation with a hematologist or oncologist?	by □ Yes	□ No		
			Proceed to question 3	STOP		
				Coverage not approved		
		Does the patient have a diagnosis of multiple myeloma?	□ Yes	□ No		
			Proceed to question 4	Proceed to question 11		
		Has the patient had disease progression while on a bortezomib (Velcade) or a carfilzomib (Kyprolis) - containing regimen?		□ No		
			STOP	Proceed to question 5		
			Coverage not approved			
		Has the patient had adverse drug reactions/ adverse drug event/ allergy or is not a candidate for bortezomib AND carfilzomib?	□ Yes	□ No		
			Proceed to question 8	Proceed to question 6		
		Has the patient had adverse drug reactions/ adverse drug event/ allergy or is not a candida	nte 🗆 Yes	□ No		
		for carfilzomib and has high risk cytogenetics?		Proceed to question 7		
		Will the patient be starting Ninlaro as the third (or higher) line of therapy?	(or 🗆 Yes	□ No		
			Proceed to question 8	STOP		
				Coverage not approved		

# Prior Authorization Request Form for ixazomib **(Ninlaro)**

		Will the requested medication be used in	□ Yes	□ No
		combination with lenalidomide (Revlimid), pomalildomide (Pomalyst), OR thalidomide	Proceed to question 9	STOP
		(Thalomid)?		Coverage not approved
	9.		□ Yes	□ No
	combination with dexamethasone?	Proceed to question <b>10</b>	STOP	
			Coverage not approved	
	10.	Will the patient be using the requested medication concurrently with bortezomib or carfilzomib?	□ Yes	□ No
			STOP	Sign and date below
		Coverage not approved		
	11. Please provide the diagnosis.			
			Proceed to question <b>12</b>	
	12.	<ol> <li>Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B</li> </ol>	□ Yes	🗆 No
			Sign and date below	STOP
	recommendation?		Coverage not approved	
Step Ic	certif	y the above is true to the best of my knowl	edge. Please sign and c	late:

5

Prescriber Signature

Date

[14 August 2019]

For Internal Use Only	
Approved:	Duration of Approval:month(s)
Denied:	Authorized By:
Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: